Abstract Search

ey0021.11-4 | Interventions for Weight Loss: New Findings | ESPEYB21

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

CL Roth , C Scimia , AH Shoemaker , M Gottschalk , J Miller , G Yuan , S Malhotra , MJ Abuzzahab

Brief Summary: This phase 2, open-label, multicenter trial examined the efficacy of setmelanotide, a melanocortin-4 receptor agonist, in patients aged 6 to 40 years with obesity due to hypothalamic injury. Setmelanotide reduced body mass index (BMI) and hunger levels in most participants; 89% achieved a reduction in BMI of at least 5% after 16 weeks. These results indicate that setmelanotide is a promising treatment for hypothalamic obesity.This phase 2 ...

0 shares

ey0015.11-16 | BAT: The story goes on | ESPEYB15

11.16 Non-invasive Measurement of Brown Fat Metabolism Based on Optoacoustic Imaging of Hemoglobin Gradients

J Reber , M Willershäuser , A Karlas , K Paul-Yuan , G Diot , D Franz , T Fromme , SV Ovsepian , N Bézière , E Dubikovskaya , DC Karampinos , C Holzapfel , H Hauner , M Klingenspor , V Ntziachristos

To read the full abstract: Cell Metab. 2018, 27, 689-701The gold standard for the determination of BAT activity is the measurement of glucose uptake upon cold exposure using [18F]-FDG PET/CT. However, due to the use of ionizing radiation, this technique cannot be used repeatedly in longitudinal studies in humans. Alternatively, magnetic resonance imaging (MRI) and near-infrared fluorescence ...

0 shares

ey0018.8-8 | Clinical Trials – New Treatments | ESPEYB18

8.8. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

K Clement , E van den Akker , J Argente , A Bahm , WK Chung , H Connors , K De Waele , IS Farooqi , J Gonneau-Lejeune , G Gordon , K Kohlsdorf , C Poitou , L Puder , J Swain , M Stewart , G Yuan , M Wabitsch , P; Setmelanotide POMC and LEPR Phase 3 Trial Investigators Kuhnen

Lancet Diabetes Endocrinol. 2020 Dec;8(12):960970.https://pubmed.ncbi.nlm.nih.gov/33137293/This article reports the results of two single-arm, open-label, multicentre, phase 3 trials of the MC4R agonist, setmelanotide, in patients with severe obesity due to pro-opiomelanocortin (POMC) deficiency or leptin receptor (LEPR) deficiency. Mean % change in bodyweight after ~1 year was &#8722...

1 shares

ESPE Yearbook of Paediatric Endocrinology

11.4. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial

11.16 Non-invasive Measurement of Brown Fat Metabolism Based on Optoacoustic Imaging of Hemoglobin Gradients

8.8. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials

BiosciAbstracts